Literature DB >> 4389137

Microbiological and pharmacological behavior of 7-chlorolincomycin.

B R Meyers, K Kaplan, L Weinstein.   

Abstract

Replacement of the 7-(R) hydroxyl group of lincomycin by a 7-chloro-substituent produced a compound with greater in vitro activity than the parent. Laboratory studies of this compound showed it to be highly active against all of the following strains of gram-positive organisms examined, including penicillinase- and nonpenicillinase-producing staphylococci, Diplococcus pneumoniae, Streptococcus viridans and Streptococcus pyogenes. The enterococci, as well as all the gram-negative organisms tested, with the exception of some strains of Haemophilus, were uniformly insensitive to this agent. The activity of 7-chlorolincomycin was not affected by serum or inoculum size. Resistance developed in a slow stepwise pattern. Peak levels of approximately 2 mug/ml were achieved in the serum of volunteers after ingestion of 150 mg either in the fasting state or after a meal. No untoward effects were noted. The antibiotic appears to be of potential value in the treatment of infections due to gram-positive organisms, with the exception of enterococcus.

Entities:  

Mesh:

Substances:

Year:  1969        PMID: 4389137      PMCID: PMC377774          DOI: 10.1128/am.17.5.653-657.1969

Source DB:  PubMed          Journal:  Appl Microbiol        ISSN: 0003-6919


  4 in total

1.  Observations on the extracellular nature of staphylococcal penicillinase.

Authors:  K R ERIKSEN; D HANSEN
Journal:  Acta Pathol Microbiol Scand       Date:  1954

Review 2.  Lincomycin.

Authors:  K Kaplan; L Weinstein
Journal:  Pediatr Clin North Am       Date:  1968-02       Impact factor: 3.278

3.  Comparison of in vitro antibacterial activities of 7-chloro-7-deoxylincomycin, lincomycin, and erythromycin.

Authors:  D W Garrison; R M DeHaan; J B Lawson
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1967

4.  Chemical modification of lincomycin.

Authors:  B J Magerlein; R D Birkenmeyer; F Kagan
Journal:  Antimicrob Agents Chemother (Bethesda)       Date:  1966
  4 in total
  12 in total

1.  A studyof the pharmacokinetics of clidamycin in normal subjects and patients with chronic renal failure.

Authors:  J B Eastwood; P E Gower
Journal:  Postgrad Med J       Date:  1974-11       Impact factor: 2.401

2.  Parenteral and oral clindamycin therapy in surgical infections: a preliminary report.

Authors:  H T Edmondson
Journal:  Ann Surg       Date:  1973-11       Impact factor: 12.969

3.  Clindamycin bioavailability from clindamycin-2-palmitate and clindamycin-2-hexadecylcarbonate in man.

Authors:  A A Forist; R M DeHaan; C M Metzler
Journal:  J Pharmacokinet Biopharm       Date:  1973-04

4.  Chemotherapy of bronchitis.

Authors:  A A Mitchell
Journal:  Br Med J       Date:  1970-05-23

5.  The effect of fenfluramine on obesity and plasma lipids of patients with renal allografts.

Authors:  S A Tomlinson; J G Lines; M A Greenfield
Journal:  Postgrad Med J       Date:  1975       Impact factor: 2.401

6.  Clinical uses and control of rifampicin and clindamycin.

Authors:  I Phillips
Journal:  J Clin Pathol       Date:  1971-07       Impact factor: 3.411

7.  In vitro activity of clindamycin and other antimicrobials against gram-positive bacteria and Hemophilus influenzae.

Authors:  M I Marks
Journal:  Can Med Assoc J       Date:  1975-01-25       Impact factor: 8.262

8.  Clindamycin plus gentamicin as expectant therapy for presumed mixed infections.

Authors:  A W Chow; J K Ota; L B Guze
Journal:  Can Med Assoc J       Date:  1976-12-18       Impact factor: 8.262

9.  Significance of Staphylococcus epidermidis in the clinical laboratory.

Authors:  F J Marsik; J T Parisi
Journal:  Appl Microbiol       Date:  1973-01

10.  In-vitro comparison of erythromycin, lincomycin, and clindamycin.

Authors:  L Phillips; R Fernandes; C Warren
Journal:  Br Med J       Date:  1970-04-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.